“Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s397. doi:10.25251/skin.8.supp.397.